SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-047322
Filing Date
2024-04-15
Accepted
2024-04-15 16:53:16
Documents
13
Period of Report
2024-04-15
Items
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2411870d1_8k.htm   iXBRL 8-K 22361
  Complete submission text file 0001104659-24-047322.txt   197632

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA otlk-20240415.xsd EX-101.SCH 3048
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20240415_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20240415_pre.xml EX-101.PRE 22381
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2411870d1_8k_htm.xml XML 3777
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 24845245
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)